Rome, November 6. (Adnkronos Health) – “The life sciences sectors, including pharmaceuticals, are a huge industrial heritage for which all countries are competing at this time, putting in place very important incentives. Italy starts from an advantageous position, namely a very strong industrial structure that has grown in recent years and excels in both production and research, also thanks to many public centers with which we collaborate assiduously.” Thus Carlo Riccini, general director of Farmindustria, participating in the meeting, in Rome, on ‘The impact of Roche and the value of Biotech: the sector as a driver of development and growth for Italy’.
The Italian pharmaceutical sector is therefore an excellence for the country, but “we operate in a context of very strong international competition – explains Riccini – All countries compete for this jewel, which are the new technologies of life sciences, so we must be very good at maintaining what we have and investing in the future. We certainly need more resources because the demand for health, from an aging society seeking well-being, grows physiologically.”
Not only that, “we also need a new way of using” resources, “trying to optimize care pathways – specifies Riccini – so not necessarily rationalizing or cutting them, but dedicating resources where needed and valuing positive externalities, i.e., the advantages that treatments determine for both health and productivity. Finally, we need rules to be faster in attracting investments, on which we can attract more and more. All countries are racing to get there – he states – If we are better, we can leverage what we already have, be quick and increase investments, which do not cost public resources but private resources. Resources that are distributed internationally and can bear fruit in our territories, at a national level and in all regions,” he concludes.